CYDX (Cyduct Diagnostics) Beta: 1.3024 (As of Jun. 27, 2026)


What is Cyduct Diagnostics Beta?

Cyduct Diagnostics CYDX +4.22% Beta is 1.3024 as of Jun. 27, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Cyduct Diagnostics's Beta is 1.3024.

Cyduct Diagnostics  (OTCPK:CYDX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Cyduct Diagnostics Beta Related Terms

Cyduct Diagnostics Beta Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Beta Chart

Cyduct Diagnostics Annual Data
Trend
Beta

Cyduct Diagnostics Quarterly Data
Beta

CYDX vs SECI, QTXB, ASNB: Beta Comparison

For the Medical Devices subindustry, Cyduct Diagnostics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyduct Diagnostics Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyduct Diagnostics's Beta distribution charts can be found below:

* The bar in red indicates where Cyduct Diagnostics's Beta falls into.


Cyduct Diagnostics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.3024 mean?
Cyduct Diagnostics (CYDX) has a Beta of 1.3024 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Beta too high?
Cyduct Diagnostics' current Beta is 1.3024.
How does Cyduct Diagnostics' Beta compare to SECI and QTXB?
Cyduct Diagnostics' Beta of 1.3024 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Beta is 1.3024. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Beta of 1.3024. The current Beta is 1.3024. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Beta is 1.3024 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.